These concentrations inhibit platelet activation and aggregation. Patients included in the study received ASA 25mg bid, ER dipyridamole 200mg bid, a combination of both, or placebo. All three drug groups demonstrated a statistically significant reduction compared to placebo. However, when the drug groups were compared to each other, the combination product showed a statistically significant risk reduction when compared to both ASA and ER dipyridamole. The ESPS 2 trial endorses the use of this combination product and demonstrates its benefit over low-dose aspirin therapy or dipyridamole monotherapy.
Drug interactions are limited, and side effects are similar to aspirin or dipyridamole.
1999 Heart and Stroke Statistical Update. The value of stroke prevention and treatment. Holloway RG, Witter DM et al. Inpatient costs of specific cerebrovascular events at five academic medical centers. Ad Hoc Committee on Guidelines for the Management of Transient Ischemic Attacks, Stroke Council, American Heart Association.